A3P

Log in

Novartis: EU approval of Kisqali for breast cancer

Swiss pharmaceutical giant Novartis announced Thursday that its new drug for a form of breast cancer in postmenopausal women, called Kisqali, has been registered in the European Union.

Read more...

Roche acquires mySugr Diabetes Management Platform

The Swiss pharmaceutical group Roche will buy all the shares of mySugr, a platform for mobile diabetes management services, announced Friday without disclosing the amount of the transaction.

Read more...

Novartis: CHMP approves breast cancer drug

Swiss pharmaceutical giant Novartis on Friday received a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP), a body of the European Union, for its new drug called Kisqali, against breast cancer.

Read more...

Servier and Transgene combine in immuno-oncology

The pharmaceutical group Servier and the Alsatian biotech Transgene announced on Thursday a research agreement on the application of technologies called "viral vectorization" to developing cell therapies in the field of immuno-oncology.

Read more...

Eurofins strengthens in clinical analysis in Italy

The French group of biopharmaceutical, environmental and food analysis services Eurofins announced on Tuesday the acquisition of the Italian company Genoma Group, specializing in clinical tests.

Read more...

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P